MAPT and Alzheimer disease: Post hoc testing revealed that compared to controls, there was a difference in FTLD‐TDP (p < 0.001), FTLD‐tau (p = 0.01) and FTLD‐FUS (p < 0.001) subgroups, but not in AD (p = 0.92) (Figure 2A).